Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
The Uromigos: Kidney Cancer
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news on kidney cancer.
Advertisement
Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial.
Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313.
David Braun, MD, PhD joins the show to discuss his Nature paper on a personalized RCC vaccine.
Professor Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy in RCC tumors.
Dr. David McDermott joins the podcast to review the top data from 2024 in the renal cell carcinoma field.
Dr. Jim Brugarolas joins the podcast to discuss his talk from IKCS 2024 and the broad topic of resistance to HIF inhibitors.
Dr. Andrew Smith, chair of diagnostic imaging at St. Jude's, joins the podcast to discuss the emerging field of radiomics.
Listen to the podcast format of the kidney cancer panel on IO after IO therapy from Uromigos Live 2024.
Listen to the podcast format of the kidney cancer panel on TKI vs Ipi/Nivo vs IO/TKI from Uromigos Live 2024.
Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024.
Lothar Bergmann describes this investigator-initiated trial of Ipi/Nivo vs SOC in Non-clear Cell RCC.
Brad McGregor joins Brian and Tom to discuss a new HIF inhibitor, NKT2152, and preliminary data in RCC.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers.
Naomi Haas joins Tom and Brian in New York City at the World GU Conference to discuss several RCC topics.
Dr. Eric Jonasch discusses the process of guideline modification and updates in adjuvant, front-line and refractory RCC.
Dr. David Braun discusses his organization of immune therapies into four groups and describes novel treatments and targets.
Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos.
Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup.
Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round.
Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup.
Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup.
Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting.
The Uromigos discuss adjuvant therapy in kidney and bladder cancer trials including KEYNOTE-564.
Dr. McDermott discusses the similarities between current melanoma trials and kidney cancer treatments.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Cristina Suarez discusses the biggest RCC trials of 2023.
Tian Zhang joins the podcast to give an overview of some of the panels presented at this year's IKCS meeting.
Xinan Sheng, MD, joins the podcast to discuss the RENOTORCH trial on toripalimab plus axitinib for advanced RCC.
Dr. Lisa Pickering discusses 3 different renal cancer abstracts that were presented at ESMO 2023.
Dr. Toni Choueiri discusses progress in systemic therapy for papillary renal cell carcinoma, as well as personalized therapy.
Dr. Celeste Simon discusses her career in translational science and kidney cancer at the University of Pennsylvania.
Dr. Laurence Albiges discusses biomarker studies and new combinations and therapies presented at the KCRS23 meeting.
Rachel Giles, MD, PhD, describes her patient data on adjuvant and first line treatments in renal cell carcinoma.
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
Bob Motzer, MD, joins the discussion on IPI/Nivo versus VEGF/PD1 to give his perspective on the recent debate from ASCO 2023.
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
A summary of the renal cancer session of the Conversations & Trending Topics in GU Cancers conference in the Canary Islands.
Monty Pal, MD, FASCO, discusses his recent study on the use of novel CAR T-cell therapy for renal cell carcinoma.
David McDermott, MD, debates the role of ipilimumab for clear cell renal cancer with Uromigos host Brian Rini, MD.
Pavlos Msaouel chats with The Uromigos about his editorial on the results of the recent COSMIC-313 trial.
The Uromigos chat with Dan Shapiro, Assistant Professor of Urologic Oncology, on his work in renal medullary carcinoma.
The Uromigos chat with Scott M. Haake for the second episode of their Rising Star series and discuss his latest project.
The Rising Star series starts with Renee Saliby, a postdoctoral GU oncology research fellow at Dana-Farber Cancer Institute.
Toni Choueiri describes the COSMIC-313 trial on cabozantinib with nivolumab and ipilimumab in advanced or metastatic RCC.
Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer.
Kimryn Rathmell, MD, PhD, discusses highlights from the kidney cancer guidelines presented at the ASCO Annual Meeting.
Darren Feldman describes different approaches to relapsed germ cell tumors and the TIGER study.
David Braun gives an overview of the mechanisms of response to PD1 therapy in renal cancer.
Michael Staehler gives an overview of the abstracts presented in the oral session from EIKCS 2022.
Dr. David McDermott attempts to get his point across he discusses favorable risk clear cell renal cancer and its treatments.
Dr. Laurence Albiges gives an overview of the new ESMO RCC guidelines, and Brian challenges her and Tom.
Dr. David Cella unpacks the data across these studies and makes some conclusions.
Dr. David McDermott describes his clinical cancer research paper on treatment-free survival in kidney cancer.
Chad Tang discusses his oncology paper recently published in Lancet.
Tom and Brian take a look back at the year in kidney cancer with Dr. Toni Choueiri.
Dr. Mike Atkins discusses the role of CTLA4 inhibition in RCC.
Betsy Plimack discusses the tricks of the trade for adverse event management.
Dr. Janet Brown discusses intermittent VEGF TKI therapy in the context of the STAR clinical trial.
Dr. Naveed Vasudev discusses IPI dosing and findings from the PRISM study.
Dr. Nick Vogelzang discusses his career and describes treatment advances in renal cell carcinoma.
Dr. Grant Stewart discusses renal cancer data presented at the 2021 EAU Conference.
Dr. Nizar Tannir and the Uromigos discuss the phase 3 trial of cabozantinib +/- a glutaminase inhibitor in refractory mRCC.
The Uromigos discuss a plenary presentation on adjuvant pembrolizumab versus placebo in high-risk resected RCC.
The Uromigos and Monty Pal discuss data on microbiome modification's impact on immune-oncology clinical efficacy in mRCC.
Dr. James Larkin describes what can be learned from adjuvant immune checkpoint inhibitors in melanoma.
Dr. Eric Jonasch gives an overview of his paper published in Nature Medicine.
Dena Battle discusses misinformation that patients may be exposed to through social media and how it can be avoided.
Dr. Samra Turajlic summarized the meetings at the 2021 European International Kidney Cancer Symposium.
Dr. Viktor Grünwald discusses treatment for progression of disease after front-lines PD1-based therapy.
Dr. Toni Choueiri discusses the details of the CLEAR trial and options for patients with treatment-naive metastatic RCC.
Monty Pal discusses his randomized phase 2 study of cabozantinib in papillary renal cancer.
Dr. Eric Jonash gives a thoughtful answer to this question.
Dr. Tom Hutson joins the Uromigos for a discussion on lenvatinib and everolimus prior to the CLEAR trial presentation.
Laurence Albiges discusses highlights in renal cancer research and advancements from 2020.
Dr. Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups.
Drs. David McDermott and Brian Rini debate treatment options in front-line renal cancer.
Gretchen Vaughan, CEO of the Kidney Cancer Association, discusses the upcoming International Kidney Cancer Symposium meeting.
Dr. Toni Choueiri and the Uromigos attempt to put the data into context with the other available combinations.
Dr. David McDermott joins the Uromigos to discuss biomarkers in renal cancer in the era of immune therapy.
Dr. Axel Bex talks about small renal masses, robotic versus partial nephrectomy, and surgery in metastatic disease.
Dr. Oliver Grimm discusses the first-line renal cancer (clear cell and non-clear cell) and clinical trials.
Dr. Cristina Suarez discusses the success of clinical trials in Spain and access to treatments.
Dr. Juan Sade discusses research, treatment pathways in GU cancer, steak, and red wine in Argentina.
Dr. Bernard Escudier discusses treatment for tumors that progress after first-line immunotherapy.
Dr. Danny Heng discusses Italian food and the past, present, and future of the IMDC prognostic score.
Dr. Toni Choueiri discusses the results of this study, which appears to show a survival signal.
Mike Atkins describes the results of this study, which sheds light on the role of ipilimumab and nivolumab in this disease.
Betsy Plimack discusses the updated data from KEYNOTE 426 with a minimum of 23 months' follow up.
Dr. Tian Zhang discusses the phase 3 PDIGREE Trial for first-line treatment of metastatic clear cell renal cell carcinoma.
Dr. Monty Pal, professor of medicine at City of Hope, discusses non-clear cell renal cancer.
Dena Battle, President of KCCure, answers patient-focused questions about kidney cancer management during the pandemic.
Professor Tom Powles and Dr. Brian Rini broadcast from ASCO GU 2020, held in San Francisco.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.